Valuation : Oncopeptides AB

Market Cap 802M 83.63M 72.07M 67.57M 61.68M 116M 7.99B 117M 313M 4.03B 314M 307M 13.38B P/E 2026 *
-4.41x
P/E 2027 * -8.63x
Enterprise Value 868M 90.52M 78M 73.13M 66.76M 126M 8.65B 126M 339M 4.37B 340M 332M 14.48B EV / Sales 2026 *
7.11x
EV / Sales 2027 * 3.64x
Free-Float
96.1%
Yield 2026 *
-
Yield 2027 * -
1 day-1.07%
1 week+21.00%
Current month+28.19%
1 month+26.20%
3 months+4.64%
6 months+19.29%
Current year-57.79%
1 week 1.6
Extreme 1.6
2.16
1 month 1.55
Extreme 1.551
2.16
Current year 1.26
Extreme 1.255
4.91
1 year 1.26
Extreme 1.255
6.55
3 years 1.1
Extreme 1.1
10.2
5 years 1.1
Extreme 1.1
54.7
10 years 1.1
Extreme 1.1
215
Manager TitleAgeSince
Chief Executive Officer 46 2023-08-06
Director of Finance/CFO 52 2023-11-12
Chief Tech/Sci/R&D Officer 54 2023-08-31
Director TitleAgeSince
Director/Board Member 65 2011-12-31
Director/Board Member 63 2017-01-31
Chairman 78 2018-05-16
Date Insider Type Main position Quantity % Market Cap.
3/20/26 Free

Chief Technology Officer

3,000 0.0008%
3/18/26 Buy 14,631 0.0038%
3/17/26 Free

Investor Relations Manager

66 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-1.07%+21.00% - - 83.63M
Average -1.07%
Weighted average by Cap. -1.07%

Financials

2026 *2027 *
Net sales 122M 12.73M 10.97M 10.28M 9.39M 17.68M 1.22B 17.74M 47.6M 614M 47.79M 46.75M 2.04B 240M 25.01M 21.55M 20.21M 18.45M 34.75M 2.39B 34.86M 93.55M 1.21B 93.91M 91.87M 4B
Net income -180M -18.78M -16.18M -15.17M -13.85M -26.09M -1.79B -26.17M -70.23M -906M -70.5M -68.97M -3B -78M -8.14M -7.01M -6.57M -6M -11.31M -778M -11.34M -30.43M -393M -30.55M -29.89M -1.3B
Net Debt 66M 6.89M 5.93M 5.56M 5.08M 9.57M 658M 9.6M 25.75M 332M 25.85M 25.29M 1.1B 70.5M 7.35M 6.34M 5.94M 5.42M 10.22M 703M 10.25M 27.51M 355M 27.61M 27.01M 1.18B
Logo Oncopeptides AB
Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
Employees
77
Date Price Change Volume
26-08-28 SEK 2.028 -1.07% 8,473,388
26-08-27 SEK 2.050 +20.45% 22,539,222
26-08-26 SEK 1.702 +3.03% 1,777,960
26-08-25 SEK 1.652 +0.43% 2,560,720
26-08-24 SEK 1.645 -1.85% 1,376,295
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
2.028SEK
Average target price
2.467SEK
Spread / Average Target
+21.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ONCO Stock